We have examined the possible renoprotective effect of felodipine 5 mg orally, given daily for 5 days before operation, in 29 patients undergoing elective infrarenal aortic surgery in a randomized, blinded and placebo-controlled study. Effective renal plasma flow (ERPF), glomerular filtration rate (GFR), urine output, fractional sodium clearance and plasma concentrations of angiotensin II, aldosterone, arginie vasopressin and atrial natriuretic peptide did not differ between the felodipine and placebo groups. ERPF and GFR were not reduced after operation in the placebo group. In the felodipine group, GFR was higher 24 h after operation compared with before operation. We conclude that increased GFR in the felodipine group, measured 24 h after operation, may indicate a beneficial effect of felodipine but in the present context this was not clinically important. Felodipine had no significant effect on vasoactive hormones. (Br.
It is not known why effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) decrease after cross-clamping of the infrarenal aorta 1 2 or why reduced renal blood flow is associated with decreased postoperative creatinine clearance. 3 The cause of this renal impairment is probably multifactorial.
Calcium antagonists cause vasodilatation at raised tone in afferent renal arterioles and ameliorate experimental renal ischaemia. 4 Felodipine is a dihydropyridine calcium antagonist, characterized by high vascular selectivity, which causes a reduction in systemic vascular resistance, and has no adverse effects on myocardial contractility or conduction.
In this prospective, randomized, placebocontrolled study, we have examined if treatment with felodipine for 5 days before operation influenced ERPF, GFR, fractional excretion of sodium and potassium, osmolar clearance or vasoactive hormones in elective surgery for infrarenal atherosclerosis.
Patients and methods
We studied 29 patients with aorto-iliac occlusive arterial disease undergoing elective aorto-biliac or aorto-bifemoral graft implantation. The study was approved by the Danish National Health Board and the local Ethics Committee, and all patients gave written informed consent. One of the authors (L. de L.) anaesthetized all patients.
Patients were invited to participate in the study if kidney function was normal after diethyltriamine-pentaacetic acid (DTPA) renography. Exclusion criteria were: age more than 70 yr; myocardial infarction within the past year; cardiovascular symptoms or receiving medications; unstable angina or stable angina with congestive heart failure; symptomatic cerebrovascular disease; diabetes mellitus; diastolic arterial pressure ജ100 mm Hg; cardiac valvular stenosis with haemodynamic implications; systemic therapy with bronchodilators or steroids; or treatment with a calcium antagonist or an angiotensin converting enzyme inhibitor.
Patients were excluded during the study if they experienced postoperative pain requiring replacement of extradural catheter, loss of more than 50% of estimated blood volume or there were technical failures during sampling.
FELODIPINE TREATMENT AND SIDE EFFECTS
The randomization and preparation of felodipine extended release tablets (5 mg) and placebo were undertaken by Astra AB, Sweden. This dose was chosen because patients were normotensive. Felodipine treatment was started 5 days before operation, after a clearance test. The day before operation, patients were asked if they had any complaints relating to felodipine treatment including, ankle oedema, headache, flushing, palpitations, dizziness or tiredness. All patients received their last felodipine dose 1.5-2.5 h before anaesthesia.
RENAL HAEMODYNAMICS, HORMONES AND ELECTROLYTES
ERPF and GFR were measured before treatment with felodipine or placebo and twice after operation (when patients were haemodynamically stable, 1 h after operation and 24 h after operation). On these three occasions, plasma concentrations of angiotensin II, aldosterone, arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) were measured. On the same three occasions, plasma concentrations of electrolytes were analysed for calculation of clearances of sodium, potassium and water, and osmolality was also measured. Plasma concentrations of felodipine were measured 1 and 24 h after operation.
ANAESTHESIA AND ANALGESIA Premedication comprised diazepam 10-15 mg orally, 1 h before anaesthesia. An extradural catheter was inserted at T10-11 or one segment above, and 0.5% plain bupivacaine 6-10 ml was administered as a bolus followed by an infusion of 5 ml h
91
. General anaesthesia was induced with midazolam 2.5-5 mg, fentanyl 3-5 g kg 91 and thiopentone 50-250 mg. The trachea was intubated after administration of pancuronium 1 mg and suxamethonium 75-100 mg i.v. A bolus dose of pancuronium 6-8 mg was given to achieve neuromuscular block. Anaesthesia was maintained with 0.4-1.0% halothane. Signs of patient discomfort during surgery (increased heart rate or arterial pressure, dilated pupils or sweating) were treated with extradural bupivacaine 3 ml at incision and later with alfentanil 0.5 mg i.v. Hypotension was treated with a bolus dose of ephedrine 2-5 mg or noradrenaline 2-5 g (if systemic vascular resistance was :800 dyn s cm 95 ) while corrective measures were taken in terms of fluid infusion and adjustment of the level of anaesthesia. Dopamine 3 g kg 91 min 91 was administered after insertion of the pulmonary artery catheter until 06:00 the next morning. The trachea was extubated at the end of operation. After operation, extradural infusion continued with 0.17% plain bupivacaine 5-8 ml h 91 until midnight. In the intensive care unit, extradural morphine 3-4 mg was injected every 6-8 h. Diuretics were not administered during the study. Droperidol bolus doses of 1.25 mg were used as an antiemetic.
MONITORING
The ECG (leads II and V5) was monitored continuously. A 5-French thermodilution pulmonary artery catheter was inserted via the right internal jugular vein and a nasopharyngeal temperature probe, nasogastric tube and urinary bladder catheter inserted. During operation, systemic mean arterial pressure (MAP), pulmonary artery mean pressure (PAMP), heart rate (HR) and central venous pressure (CVP) were displayed continuously. Pulmonary artery wedge pressure (PAWP) and cardiac output were measured as required, and cardiac index (CI), stroke volume index (SVI) and systemic vascular resistance (SVR) were calculated. Haemodynamic observations were recorded five times during operation in all patients (before skin incision; before aortic cross-clamping; 5 min after clamping; at completion of vascular anastomoses; and at the end of operation) and at the same times as the postoperative clearance measurements.
Systemic arterial blood samples were analysed to ensure normocapnic ventilation and adequate oxygenation during operation.
FLUID TREATMENT
Before skin incision, fluid was administered to compensate for vasodilatation caused by extradural and general anaesthesia: Dextran 70, 60 mg ml 91 with isotonic sodium chloride 300-400 ml m 92 body surface area and an equal volume of isotonic saline. During operation, isotonic saline was infused to compensate for evaporation and third space loss: 600 ml m 92 , 400 ml m 92 and 200 ml m 92 in the first, second and third hours of operation, respectively. In addition, isotonic saline was given in a volume equivalent to the volume of urine produced during the previous hour of operation. Blood loss was compensated for by Dextran 70 up to a maximum dose of 1.5 g kg 91 and then human albumin was given. If packed cell volume was less than 0.28, SAG-M blood was transfused during and after operation.
After operation, crystalloid was infused at a rate of 60 ml m 92 h 91 until the next morning at 06:00 and at 120 ml m 92 h 91 thereafter. Human albumin was given if hypovolaemia occurred (hypotension at low PAWP and normal SVR).
LABORATORY ANALYSES GFR and ERPF were measured by the constant infusion clearance method. Cr-EDTA and 125 Ihippuran, respectively, in the other patients, because of administrative changes. The same method was used in each patient.
Angiotensin II was measured by radioimmunoassay using a modification of the method described by Kappelgaard, Nielsen and Giese. 6 The minimum detection level in plasma was 2 pmol litre 91 . Coefficients of variations were 12% (inter-assay) and 8% (intra-assay). Aldosterone was measured by a slight modification of a method described previously. 7 The minimum detection level was 42 pmol litre
91
. Coefficients of variation were 13% (inter-assay) and 9% (intra-assay). Atrial natriuretic peptide was measured by radioimmunoassay as described previously. 8 The minimum detection level in plasma was 0.5 pmol litre
. Coefficients of variation were 12% (inter-assay) and 10% (intraassay). Arginine vasopressin was measured radioimmunologically by a slight modification of a method described previously. 9 The minimum detection level was 0.5 pmol litre
. Coefficients of variation were 13% (inter-assay) and 9% (intra-assay). Plasma felodipine assays were conducted by Astra AB, Sweden. Clearance data were standardized to a body surface area of 1.73 m 2 .
STATISTICAL ANALYSIS
In a previous study with similar patients, 11 there were 12 patients in each group and the SD for preoperative GFR was 17.5 ml min
91
. With a minimum relevant difference between means of 26.3 ml min 91 , ␣:0.05 and ␤:0.10, the number of patients required in each group was calculated as nine. The Mann-Whitney and non-parametric two-way analysis of variance tests were used (significance level 0.05). Intra-group differences were examined by the Wilcoxon test (significance level 0.02). Unless otherwise specified, results are presented as median (interquartile ranges).
Results
There were 14 and 15 patients in the felodipine and placebo groups, respectively. Patients were not receiving cardiorespiratory drugs, except for one patient in the felodipine group who was treated with a diuretic for hypertension; this patient was not excluded.
Side effects of felodipine included headache in one patient, and another was exceptionally tired. One other patient reported palpitations, and one had flushing of the face and oedema of the ankles and fingers. In the placebo group, one patient confessed to all side effects. One patient complained of headache and one suffered from dizziness.
Three patients were excluded from each group. In the felodipine group one patient developed influenza after randomization and the operation was cancelled; one patient lost excessive quantities of blood during operation; and the third patient had the extradural catheter replaced. In the placebo group, one patient lost excessive quantities of blood, one had replacement of the extradural catheter and one was excluded because of technical problems. Table 1 describes the 23 patients who completed the study. Age, weight and height in the two groups were well matched.
There were no major complications during or after operation. In the felodipine group, one patient developed sinus bradycardia on day 4 after operation. One patient developed a silent subendocardial infarction during the night before operation. She was discharged home 8 days after operation in good health. One patient in the placebo group had atrial fibrillation.
Duration of operation, aortic clamping time and intraoperative blood loss (table 2) were similar in the two groups. The number of patients who received bolus doses of ephedrine/noradrenaline was 6/4 in the felodipine group and 7/7 in the placebo group. Hypotension (SVR 430-813 dyn s cm
95
) on the night after operation was treated with infusion of noradrenaline in two patients in the felodipine group and in four patients in the placebo group. Two patients in the placebo group required infusion of noradrenaline during the last postoperative clearance measurement.
CENTRAL HAEMODYNAMICS
Mean preoperative arterial pressure (table 1) was unchanged in the felodipine group. There was no difference between the groups in central haemodynamic variables during operation (PAWP, CVP, HR, MAP, PAMP, CI, SVI and SVR). There was a time-treatment interaction for CVP and PAMP (P:0.033 and 0.035). CVP, PAMP and PAW are shown in figure 1 and HR, MAP and CI in table 3. We did not estimate intra-group differences as haemodynamic variations are expected during major vascular procedures.
RENAL HAEMODYNAMICS
The two groups did not differ in ERPF and there was no time-treatment interaction. In both groups ERPF was increased at the first postoperative clearance test (felodipine P:0.004; placebo P:0.002) compared with the preoperative level ( fig. 2) . GFR ( fig. 2 ) did not differ in the two groups, there was a Figure 2 Effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) (means of 2-3 measurements) in the felodipine and placebo groups at: 0:preoperative measurement, 1:first postoperative measurement (haemodynamic stability 1 h after operation), 2:second postoperative measurement (24 h after operation). ERPF: there was no difference between groups, but ERPF was increased at the first postoperative clearance test in both groups compared with preoperative levels. GFR: there was no difference between groups but there was a time-treatment interaction, and GFR was increased 24 h after operation in the felodipine group compared with preoperative values. :Median value. time-treatment interaction (P:0.049) and GFR was increased 24 h after operation in the felodipine group compared with preoperative values (P:0.016). The two groups did not differ in filtration fraction, and there was no time-treatment interaction. In both groups the filtration fraction was lower at the first postoperative clearance test than at the preoperative test.
WATER AND ELECTROLYTE CLEARANCE
Urine output was similar in the two groups: 310 (160-560) ml in the felodipine group compared with 490 (236-950) ml in the placebo group during operation, and 1815 (1494-2270) ml in the felodipine group and 2023 (1438-2385) ml in the placebo group until the next morning. Fractional sodium excretion, fractional potassium excretion and osmolar clearance did not differ between the two groups, and there was no time-treatment interaction. Intra-group differences are shown in table 4. Free water clearance did not differ between groups, but there was a time-treatment interaction (P:0.027). Intra-group differences are shown in table 4.
VASOACTIVE HORMONES
There were no group differences or time-treatment interactions for angiotensin II, aldosterone, atrial natriuretic peptide or vasopressin concentrations. In the felodipine group, angiotensin II was increased at both postoperative clearance tests compared with preoperative values, and ANP was increased in both groups for both tests after operation compared with preoperative values (fig. 3) . Aldosterone concentrations were increased to three times preoperative levels at the first postoperative clearance test but returned to preoperative values after 24 h (table 5) 
Discussion
Felodipine did not improve postoperative renal function compared with placebo, and ERPF and GFR were not reduced in the placebo group. The increased GFR, 24 h after operation in the felodipine group, may indicate a beneficial effect of felodipine but in the present context it was not clinically important. Using the same clearance method, Gamulin and colleagues 1 2 demonstrated intraoperative reduction in renal blood flow and GFR after infrarenal aortic clamping. We undertook a Figure 3 Angiotensin II and atrial natriuretic peptide concentrations (median and interquartiles) in the felodipine and placebo groups. 0: Preoperative measurement, 1: first postoperative measurement (haemodynamically stable, 1 h after operation), 2:second postoperative measurement (24 h after operation). Angiotensin II: there were no inter-group differences but angiotensin II concentrations were increased in the felodipine group at both postoperative clearance tests. ANP: there were no inter-group difference but ANP concentrations were increased at both postoperative clearance tests in both groups.
postoperative study as it was not possible to maintain stable central and renal haemodynamics during surgery; these are necessary to achieve valid results. The plasma concentrations of felodipine were less than the therapeutic level for antihypertensive treatment, the lower level being 2.5 nmol litre
91
. 10 To our knowledge the therapeutic plasma concentration for prevention of renal ischaemic damage is unknown.
Ours is the first randomized, placebo-controlled study of the renal effects of administration of a calcium antagonist in abdominal aortic surgery. Our results did not establish any benefit from treatment with low-dose felodipine, but the number of patients was small and there was a risk of a type II error. Our results did not excluded the possibility that felodipine may be beneficial in patients with a higher risk of reduced renal function after operation or that felodipine may be beneficial at higher plasma concentrations. The use of dopamine and high filling pressures may have prevented postoperative deterioration in renal function and therefore masked any effect of felodipine.
There was a difference between the groups in administration of vasoconstrictors. The increased ERPF at the first postoperative clearance test in both groups can be attributed to dopamine 11 as the effect of vasoconstrictors administered during operation had disappeared at this stage. ERPF measured 24 h after operation was similar to preoperative values, even during treatment with felodipine. ERPF values in the placebo group indicated neither renal vascular vasoconstriction nor vasodilatation at this stage.
Urine output and fractional excretion of sodium did not differ between the groups. Felodipine has natriuretic and diuretic effects immediately after single dose administration but these effects are less pronounced after days of drug administration. 12 13 Patients had an excellent outcome. Complications were minor in the context of postoperative morbidity after major vascular surgery. 14 15 Patients in our study were a selected group without symptomatic coronary atherosclerosis. The complication rate was the same as in the treatment group in our previous study, 11 which compared the effect of dopamine 3 g kg 91 min 91 with placebo in a similar population with the same anaesthetic and operative procedures. The conclusion of that study was that low-dose dopamine relieved cardiovascular depression caused by combined extensive thoracic extradural block and general anaesthesia, and therefore an inotropic adjuvant should accompany this anaesthetic technique.
Felodipine was tolerated well, and side effects were the same in the placebo group. In hypertensive patients, the expected cardiovascular effect of felodipine is a reduction in arterial pressure because of lower peripheral vascular resistance and a higher cardiac index. 16 During operation, mean arterial pressure, heart rate, cardiac index and systemic vascular resistance index were the same in the two groups. Any possible effect of felodipine was not discernible in the presence of operative stress, anaesthesia and low-dose dopamine. The reason for the slightly higher central venous arterial pressure and mean pulmonary artery pressure in the felodipine group is not obvious. Cardiac index did not differ between the groups which indicates that there was no severe depression of ventricular function. Pulmonary artery wedge pressure showed the same trend but was not significant. One would expect concentrations of atrial natriuretic peptide to differ between groups if the trend in these pressures represented imminent heart failure.
Administration of a dihydropyridine calcium antagonist was accompanied by increased plasma concentrations of angiotensin II and unchanged plasma aldosterone concentrations. 12 17 In this study, aldosterone was increased after operation as expected, but there was no difference between the groups. Twenty-four hours after operation aldosterone concentrations were the same as those measured before operation which may indicate that fluid administration was adequate. Perhaps ANP was increased after operation in both groups as an indication of generous fluid treatment but the levels were moderate compared with those found in heart failure. 18 19 Our observations mirror the modulating balance between the vasoconstrictor/sodiumretaining effect of the renin-angiotensin-aldosterone system and the vasodilating/diuretic-natriuretic effects of the natriuretic peptides. 20 AVP increased after operation, as observed previously in patients treated with low-dose dopamine, 11 whereas AVP was not increased after operation in the placebo group.
11
Nausea and opioids are well known triggers of AVP release, 21 22 but the physiological significance of this finding is not obvious.
